title: Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma.
abstract: Background. Endometrial stromal sarcomas (ESS) are a subtype of gynaecological sarcomas characterized by the overexpression of hormone receptors. Hormone treatment is widely used in ESS but primary or acquired resistance is common. The mammalian target of rapamycin (mTOR) pathway has been suggested to play a key role in the mechanisms of hormone resistance. Recent studies in breast and prostate cancer demonstrate that this resistance can be reversed with the addition of an mTOR inhibitor. This phenomenon has never been reported in ESS. Methods. We report the outcome of one patient with pretreated, progressing low grade metastatic ESS treated with medroxyprogesterone acetate in combination with the mTOR inhibitor sirolimus. Results. Partial response was achieved following the addition of sirolimus to the hormone treatment. Response has been maintained for more than 2 years with minimal toxicity and treatment is ongoing. Conclusion. This case suggests that the resistance to the hormone manipulation in ESS can be reversed by the addition of an mTOR pathway inhibitor. This observation is highly encouraging and deserves further investigation.
authors.affiliation: The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.
authors.forename: J
authors.initials: J
authors.lastname: Martin-Liberal
authors.affiliation: The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.
authors.forename: C
authors.initials: C
authors.lastname: Benson
authors.affiliation: The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.
authors.forename: C
authors.initials: C
authors.lastname: Messiou
authors.affiliation: The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.
authors.forename: C
authors.initials: C
authors.lastname: Fisher
authors.affiliation: The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.
authors.forename: I
authors.initials: I
authors.lastname: Judson
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: J Clin Oncol. 2012 Jan 1;30(1):78-84
references.pmid: 22067397
references.citation: J Biol Chem. 2009 Mar 6;284(10):6361-9
references.pmid: 19112174
references.citation: Expert Rev Anticancer Ther. 2012 Jul;12(7):885-94
references.pmid: 22845404
references.citation: Curr Opin Oncol. 2007 Jul;19(4):347-52
references.pmid: 17545798
references.citation: FEBS Lett. 2010 Jan 4;584(1):124-8
references.pmid: 19925796
references.citation: Gynecol Oncol. 2006 Jun;101(3):464-9
references.pmid: 16368128
references.citation: Mol Cell Endocrinol. 2013 Feb 25;366(2):170-9
references.pmid: 22801104
references.citation: Mol Cancer Ther. 2013 Nov;12(11):2342-55
references.pmid: 23966621
references.citation: Clin Cancer Res. 2011 Apr 1;17(7):1649-57
references.pmid: 21372223
references.citation: Med Oncol. 2011 Sep;28(3):771-4
references.pmid: 20354812
references.citation: Ann Oncol. 2012 Sep;23 Suppl 10:x151-7
references.pmid: 22987952
references.citation: Cancer Imaging. 2013 May 02;13:197-211
references.pmid: 23649384
references.citation: Tumour Biol. 2011 Jun;32(3):451-9
references.pmid: 21161468
references.citation: Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S
references.pmid: 14734488
references.citation: N Engl J Med. 2003 Jun 12;348(24):2431-42
references.pmid: 12802030
references.citation: Pediatr Blood Cancer. 2011 Dec 1;57(6):943-9
references.pmid: 21793180
references.citation: Eur J Radiol. 2011 Apr;78(1):30-40
references.pmid: 21247711
references.citation: Br J Cancer. 2008 Oct 21;99(8):1210-5
references.pmid: 18813312
references.citation: Gynecol Oncol. 2009 Dec;115(3):466-71
references.pmid: 19767065
references.citation: J Clin Oncol. 2007 May 1;25(13):1753-9
references.pmid: 17470865
references.citation: Gynecol Oncol. 2003 Jul;90(1):170-6
references.pmid: 12821359
references.citation: Lancet Oncol. 2009 Dec;10(12):1188-98
references.pmid: 19959075
references.citation: J Natl Cancer Inst. 2006 Sep 20;98(18):1285-91
references.pmid: 16985247
references.citation: J Clin Oncol. 2001 May 15;19(10):2596-606
references.pmid: 11352951
references.citation: Med Oncol. 2003;20(1):87-93
references.pmid: 12665689
references.citation: Semin Oncol. 2011 Jun;38 Suppl 2:S17-24
references.pmid: 21600381
references.citation: J Clin Oncol. 2000 Nov 15;18(22):3748-57
references.pmid: 11078487
references.citation: Gynecol Oncol. 2005 Oct;99(1):36-42
references.pmid: 15992918
references.citation: Gynecol Oncol. 2004 Dec;95(3):769-71
references.pmid: 15582003
references.citation: J Clin Oncol. 2013 Jul 1;31(19):2485-92
references.pmid: 23715582
references.citation: Eur J Obstet Gynecol Reprod Biol. 2009 May;144(1):80-4
references.pmid: 19269732
references.citation: Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1061s-1068s
references.pmid: 16467125
references.citation: J Clin Oncol. 2000 Nov 15;18(22):3758-67
references.pmid: 11078488
references.citation: Gynecol Oncol. 2011 May 1;121(2):323-7
references.pmid: 21277011
references.citation: N Engl J Med. 2012 Feb 9;366(6):520-9
references.pmid: 22149876
references.citation: Gynecol Oncol. 2010 Jan;116(1):131-9
references.pmid: 19853898